mRNA-Based Cancer Immunotherapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 2966
Special Issue Editor
Special Issue Information
Dear Colleagues,
Following the overwhelming success of mRNA-based vaccination in the COVID-19 pandemic, the focus of this technology has moved forward to alternative targets, including treatment of cancer.
The major, initial hurdles for mRNA-based vaccines, such as instability of mRNA, inefficient delivery, weak immunogenicity, and large-scale production, have been resolved for the COVID-19 indication. For cancer, however, these issues need to be readdressed but should, hopefully, not constitute a major obstacle.
In cancer indications, other challenges have to be overcome, such as selection of the tumor type, status and disease stage of patients, antigen(s) selection, packaging of the product (e.g., again using nanomaterials), route of administration, and immunological response and side effect rates. An additional important aspect that needs to be addressed is the feasibility of prophylactic administration of mRNA vaccination with the final objective of making therapeutic use no longer necessary.
All these issues will be addressed in this Special Issue of Biomedicines. Authors in the field of mRNA-based immunotherapy are cordially invited to submit original research or review articles contributing to this important and fast-progressing area of biomedicine.
Dr. Werner Krause
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mRNA vaccination
- cancer
- antigen selection
- nanomaterials
- clinical trials
- large-scale production
- prophylactic and therapeutic use
